Gilead Sciences

News

Gilead adds lupus, arthritis therapies with EVOQ alliance

US biotech EVOQ Therapeutics has lined up another partner for its NanoDisc immunotherapy technology, with Gilead Sciences buying into the platform in a deal valued at up to $658.5 million.<

News

Gilead grabs full rights to Jounce cancer immunotherapy

Gilead Sciences must like what it has seen in a two-year-old partnership with Jounce Therapeutics for a CCR8-targeting cancer immunotherapy – it has just agreed to take full ownership of th

News

FDA approves twice-yearly resistant HIV therapy from Gilead

Gilead Sciences has claimed FDA

News

Gilead's Kite takes control of CAR-T partner Tmunity

Gilead Sciences has bolstered its position in the development of next-generation cancer cell therapies with a deal to absorb Tmunity Therapeutics into its Kite unit.

News

SABCS: Pharmas show their working in HR+/HER2- breast cancer

The San Antonio Breast Cancer Symposium (SABCS) has highlighted some of the most promising clinical research being undertaken by drugmakers in the category, with AstraZeneca leading the cha

News

The diagnosis Hepatitis written on a clipboard

FDA rejects Gilead's hepatitis D therapy Hepcludex

Gilead Sciences has been knocked back in its quest to bring the first drug therapy for hepatitis D virus (HDV) to the US market, after the FDA rejected its marketing application.

Gilead adds lupus, arthritis therapies with EVOQ alliance

Gilead grabs full rights to Jounce cancer immunotherapy

FDA approves twice-yearly resistant HIV therapy from Gilead

Gilead's Kite takes control of CAR-T partner Tmunity

SABCS: Pharmas show their working in HR+/HER2- breast cancer

FDA rejects Gilead's hepatitis D therapy Hepcludex

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

Gilead Sciences

Editor's Picks